Franquia de hematologia fundamental da BeOne Medicines lidera próxima era da inovação em câncer de células B na EHA 2026

Key Takeaway: BeOne Medicines is poised to lead innovation in B-cell cancer treatment, as highlighted in their upcoming presentation at EHA 2026. The company focuses on hematology and aims to introduce groundbreaking therapies. Further details on specific innovations or data were not provided in the article.